Last reviewed · How we verify
NCT06563778
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Phase 2 trial testing Chidamide; Decitabine; Anti-PD-1 Antibody in Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma in 100 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 September 2024 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chidamide; Decitabine; Anti-PD-1 Antibody — full drug profile →
- Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody — full drug profile →
Conditions studied
- Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma — all drugs for Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma →
Sponsor
Chinese PLA General Hospital
Who can join
Adults 18 to 75, any sex, with Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor. This open label, randomized, phase 2 study aims to evaluate the efficacy of Chidamide+Decitabine plus Anti-PD-1 Antibody and Brentuximab Vedotin + Bendamustine plus Anti-PD-1 Antibody in transplant-ineligible or refused transplant diagnosed R/R cHL. The primary objective of the study is to evaluate progression-free survival.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.
Yang J, Zhou F, Luo X, Fang Y, et al · · 2025 · cited 10× · PMID 40032852 · DOI 10.1038/s41420-025-02366-3 -
Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.
Alibrahim MN, Gloghini A, Carbone A. · · 2024 · cited 4× · PMID 39682256 · DOI 10.3390/cancers16234070 -
Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications.
Shi R, Jia L, Lv Z, Cui J. · · 2025 · cited 2× · PMID 40909270 · DOI 10.3389/fimmu.2025.1632705 -
Impact of Tyrosine Kinase Inhibitors on the Expression Pattern of Epigenetic Regulators.
Tóth K, Gaál Z. · · 2025 · cited 1× · PMID 40282457 · DOI 10.3390/cancers17081282
Verify or expand the search:
- PubMed search for NCT06563778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chidamide; Decitabine; Anti-PD-1 Antibody
Trials testing the same drug.
- NCT06393361 — Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transpla · Phase 2 · recruiting
Other recruiting trials for Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06393361 — Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transpla · Phase 2 · recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06563778 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 21 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06563778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing